3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
60
Neoplasm Metastasis
5
Prostate Cancer Metastatic
3
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
3
Adenocarcinoma
3
Prostate CA
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Urologic Diseases
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stage IV Prostate Adenocarcinoma AJCC v7
1
Salivary Gland Neoplasms
1
Recurrence
1
Radiation Injuries
1
Prostatic Diseases
1
PSA Level Greater Than 0.03
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Neoplasm Recurrence, Local
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Lymphatic Metastasis
1
Intraprostatic Prostate Cancer
1
Hormone Sensitive Prostate Cancer
1
Genital Neoplasms, Male
1
Gastrointestinal Diseases
1
Interventions
testosterone 17 beta-cypionate
1
pembrolizumab
1
palbociclib
1
enfortumab vedotin
1
Urinary Diversion
1
Therapeutics
1
Testosterone Propionate
1
Standard of Care
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Mitomycin
1
Methyltestosterone
1
Immune Checkpoint Inhibitors
1
Health Information Exchange
1
Gemcitabine
1
Fluorouracil
1
Cystectomy
1
Cisplatin
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Diseases
×
Androgen Antagonists
×
1 year
×
Clear all
NCT07483658
2026-03-19
HYP-OP-RT
CHU de Quebec-Universite Laval
Phase NA
Not yet recruiting
434 enrolled